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Introduction
The durability of anti-tumor responses observed in
patients treated with antibodies blocking PD-1 has pro-
vided a central role for these drugs in melanoma therapeu-
tics. Identifying predictive biomarkers to aid therapeutic
decision making is critical for realizing the full potential of
these immunotherapies. We report on the development of
a pre-treatment serum test to separate melanoma patients
into two groups with significantly different outcomes fol-
lowing nivolumab therapy.
Methods
Pre-treatment serum samples were available from 119
patients in the NCT01176461 study (“SET1”) and 30
patients from an observational study (“SET2”) at two insti-
tutions. All patients had advanced un-resectable mela-
noma and received nivolumab.
Mass spectra were collected from all samples using the
“deep MALDI” approach [1]. We identified 351 mass spec-
tral peaks for use in classifier construction. SET1 was split
into a development (DEV) (N=60) and an internal validation
(VAL) (N=59) set. Deep learning methods were used to
construct a classifier correlating with time-to-event data in
a fashion similar to Roder et al [2] using only the DEV set.
This classifier was validated on the VAL set and a test was
constructed using the same procedure with the whole SET1
and performance evaluated on the independent SET2.
Results
The test separated the populations into two groups,
“Early”/”Late”, with worse/better outcome on nivolumab
treatment. The hazard ratios (HRs) between Early and
Late groups are presented in Table 1. Test classification
groups did not show any association with available
PD-L1 expression data and remained significant in mul-
tivariate analysis.
Conclusions
We have constructed a test to identify melanoma
patients most likely to have improved survival on nivo-
lumab therapy. The test validated in an independent
sample set with HR~0.3 and appears to be independent
of PD-L1 expression. Some proteins used in the test are
related to acute Phase reactions and the complement
system. While further validation and protein identifica-
tion studies are needed, this test may become a clinically
useful predictive biomarker for nivolumab therapy.
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Table 1
Set HR(TTP) Log-rank p-value HR(OS) Log-rank p-value
DEV 0.48 0.020 0.026 0.005
VAL 0.43 0.013 0.48 0.012
Full SET1 0.50 0.001 0.38 <0.001
SET2 n/a n/a 0.26 0.002
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